scispace - formally typeset
Search or ask a question
Institution

Medical University of Graz

EducationGraz, Steiermark, Austria
About: Medical University of Graz is a education organization based out in Graz, Steiermark, Austria. It is known for research contribution in the topics: Population & Medicine. The organization has 5684 authors who have published 12349 publications receiving 417282 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: The software package IPO (‘Isotopologue Parameter Optimization’) was successfully applied to data derived from liquid chromatography coupled to high resolution mass spectrometry from three studies with different sample types and different chromatographic methods and devices and the potential of IPO to increase the reliability of metabolomics data was shown.
Abstract: Background Untargeted metabolomics generates a huge amount of data. Software packages for automated data processing are crucial to successfully process these data. A variety of such software packages exist, but the outcome of data processing strongly depends on algorithm parameter settings. If they are not carefully chosen, suboptimal parameter settings can easily lead to biased results. Therefore, parameter settings also require optimization. Several parameter optimization approaches have already been proposed, but a software package for parameter optimization which is free of intricate experimental labeling steps, fast and widely applicable is still missing.

240 citations

Journal ArticleDOI
TL;DR: An overview of different methods available and applicable in clinical settings and the use of grip strength to measure muscle strength and theUse of 4-m gait speed or the Short Physical Performance Battery test to measure physical performance in daily practice are proposed.
Abstract: It is well recognized that poor muscle function and poor physical performance are strong predictors of clinically relevant adverse events in older people. Given the large number of approaches to measure muscle function and physical performance, clinicians often struggle to choose a tool that is appropriate and validated for the population of older people they deal with. In this paper, an overview of different methods available and applicable in clinical settings is proposed. This paper is based on literature reviews performed by members of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group on frailty and sarcopenia. Face-to-face meetings were organized afterwards where the whole group could amend and discuss the recommendations further. Several characteristics should be considered when choosing a tool: (1) purpose of the assessment (intervention, screening, diagnosis); (2) patient characteristics (population, settings, functional ability, etc.); (3) psychometric properties of the tool (test–retest reliability, inter-rater reliability, responsiveness, floor and ceiling effects, etc.); (4) applicability of the tool in clinical settings (overall cost, time required for the examination, level of training, equipment, patient acceptance, etc.); (5) prognostic reliability for relevant clinical outcomes. Based on these criteria and the available evidence, the expert group advises the use of grip strength to measure muscle strength and the use of 4-m gait speed or the Short Physical Performance Battery test to measure physical performance in daily practice. The tools proposed are relevant for the assessment of muscle weakness and physical performance. Subjects with low values should receive additional diagnostic workups to achieve a full diagnosis of the underlying condition responsible (sarcopenia, frailty or other).

239 citations

Journal ArticleDOI
TL;DR: Activation of FXR transcription in the intestine protects the liver from cholestasis in mice by inducing FGF15 expression and reducing the hepatic pool of BA; this approach might be developed to reverse cholESTasis in patients.

238 citations

Journal ArticleDOI
TL;DR: Actinic keratosis is a frequent health condition attributable to chronic exposure to ultraviolet radiation and several treatment options are available and evidence based guidelines are missing.
Abstract: Background Actinic keratosis (AK) is a frequent health condition attributable to chronic exposure to ultraviolet radiation. Several treatment options are available and evidence based guidelines are missing. Objectives The goal of these evidence- and consensus-based guidelines was the development of treatment recommendations appropriate for different subgroups of patients presenting with AK. A secondary aim of these guidelines was the implementation of knowledge relating to the clinical background of AK, including consensus-based recommendations for the histopathological definition, diagnosis and the assessment of patients. Methods The guidelines development followed a pre-defined and structured process. For the underlying systematic literature review of interventions for AK, the methodology suggested by the Cochrane Handbook for Systematic Reviews of Interventions, the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement and Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was adapted. All recommendations were consented during a consensus conference using a formal consensus methodology. Strength of recommendations was expressed based on the GRADE approach. If expert opinion without external evidence was incorporated into the reasoning for making a certain recommendation, the rationale was provided. The Guidelines underwent open public review and approval by the commissioning societies. Results Various interventions for the treatment of AK have been assessed for their efficacy. The consenting procedure led to a treatment algorithm as shown in the guidelines document. Based on expert consensus, the present guidelines present recommendations on the classification of patients, diagnosis and histopathological definition of AK. Details on the methods and results of the systematic literature review and guideline development process have been published separately. Conclusions International guidelines are intended to be adapted to national or regional circumstances (regulatory approval, availability and reimbursement of treatments).

238 citations

Journal ArticleDOI
Joshua C. Bis1, Charles DeCarli2, Albert V. Smith3, Fedde van der Lijn4, Fabrice Crivello5, Fabrice Crivello6, Myriam Fornage7, Stephanie Debette8, Stephanie Debette9, Joshua M. Shulman10, Joshua M. Shulman11, Helena Schmidt12, Velandai Srikanth13, Velandai Srikanth14, Maaike Schuur4, Lei Yu15, Seung Hoan Choi9, Sigurdur Sigurdsson, Benjamin F.J. Verhaaren4, Anita L. DeStefano9, Jean-Charles Lambert16, Clifford R. Jack17, Maksim Struchalin4, Jim Stankovich13, Carla A. Ibrahim-Verbaas4, Debra A. Fleischman15, Alex P. Zijdenbos18, Tom den Heijer4, Bernard Mazoyer6, Bernard Mazoyer5, Laura H. Coker19, Christian Enzinger12, Patrick Danoy20, Najaf Amin4, Konstantinos Arfanakis21, Konstantinos Arfanakis15, Mark A. van Buchem22, Renée F A G de Bruijn4, Alexa S. Beiser9, Carole Dufouil8, Juebin Huang23, Margherita Cavalieri12, Russell Thomson13, Wiro J. Niessen4, Wiro J. Niessen24, Lori B. Chibnik11, Lori B. Chibnik10, Gauti Kjartan Gislason, Albert Hofman4, Aleksandra Pikula9, Philippe Amouyel16, Kevin B. Freeman23, Thanh G. Phan14, Ben A. Oostra4, Jason L. Stein25, Sarah E. Medland26, Sarah E. Medland10, Alejandro Arias Vasquez27, Derrek P. Hibar25, Margaret J. Wright26, Barbara Franke27, Nicholas G. Martin26, Paul M. Thompson25, Mike A. Nalls28, André G. Uitterlinden4, Rhoda Au9, Alexis Elbaz8, Richard Beare14, Richard Beare29, John C. van Swieten4, Oscar L. Lopez30, Tamara B. Harris28, Vincent Chouraki16, Monique M.B. Breteler31, Monique M.B. Breteler11, Monique M.B. Breteler32, Philip L. De Jager11, Philip L. De Jager10, James T. Becker30, Meike W. Vernooij4, David S. Knopman17, Franz Fazekas12, Philip A. Wolf9, Aad van der Lugt4, Vilmundur Gudnason3, William T. Longstreth1, Matthew A. Brown20, David A. Bennett15, Cornelia M. van Duijn4, Cornelia M. van Duijn22, Thomas H. Mosley23, Reinhold Schmidt12, Christophe Tzourio8, Christophe Tzourio6, Lenore J. Launer27, M. Arfan Ikram4, Sudha Seshadri9 
TL;DR: In this article, a genome-wide association study (GWAS) of dementia-free persons (n = 9,232) identified 46 SNPs at four loci with P values of <4.0 × 10(-7).
Abstract: Aging is associated with reductions in hippocampal volume that are accelerated by Alzheimer's disease and vascular risk factors. Our genome-wide association study (GWAS) of dementia-free persons (n = 9,232) identified 46 SNPs at four loci with P values of <4.0 × 10(-7). In two additional samples (n = 2,318), associations were replicated at 12q14 within MSRB3-WIF1 (discovery and replication; rs17178006; P = 5.3 × 10(-11)) and at 12q24 near HRK-FBXW8 (rs7294919; P = 2.9 × 10(-11)). Remaining associations included one SNP at 2q24 within DPP4 (rs6741949; P = 2.9 × 10(-7)) and nine SNPs at 9p33 within ASTN2 (rs7852872; P = 1.0 × 10(-7)); along with the chromosome 12 associations, these loci were also associated with hippocampal volume (P < 0.05) in a third younger, more heterogeneous sample (n = 7,794). The SNP in ASTN2 also showed suggestive association with decline in cognition in a largely independent sample (n = 1,563). These associations implicate genes related to apoptosis (HRK), development (WIF1), oxidative stress (MSR3B), ubiquitination (FBXW8) and neuronal migration (ASTN2), as well as enzymes targeted by new diabetes medications (DPP4), indicating new genetic influences on hippocampal size and possibly the risk of cognitive decline and dementia.

238 citations


Authors

Showing all 5763 results

NameH-indexPapersCitations
Ian J. Deary1661795114161
James F. Wilson146677101883
Nancy L. Pedersen14589094696
William Wijns12775295517
Andrew Simmons10246036608
Franz Fazekas10162949775
Hans-Peter Hartung10081049792
Michael Trauner9866735543
Dietmar Fuchs97111939758
Funda Meric-Bernstam9675336803
Ulf Landmesser9456446096
Aysegul A. Sahin9332230038
Frank Madeo9226945942
Takayoshi Ohkubo9163169634
Jürgen C. Becker9063728741
Network Information
Related Institutions (5)
Mayo Clinic
169.5K papers, 8.1M citations

94% related

Brigham and Women's Hospital
110.5K papers, 6.8M citations

94% related

Baylor College of Medicine
94.8K papers, 5M citations

93% related

Beth Israel Deaconess Medical Center
52.5K papers, 2.9M citations

93% related

Boston Children's Hospital
215.5K papers, 6.8M citations

93% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
202334
2022116
20211,411
20201,227
20191,015
2018917